Literature DB >> 19347843

Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death.

Lauren E Cain1, Stephen R Cole.   

Abstract

In 1996-1997, the AIDS Clinical Trial Group 320 study randomized 1156 HIV-infected U.S. patients to combination antiretroviral therapy (ART) or highly active ART with equal probability. Ninety-six patients incurred AIDS or died, 51 (4 per cent) dropped out, and 290 (= 51 + 239, 25 per cent) dropped out or stopped their assigned therapy for reasons other than toxicity during a 52-week follow-up. Such noncompliance likely results in null-biased estimates of intent-to-treat hazard ratios (HR) of AIDS or death comparing highly active ART with combination ART, which were 0.75 (95 per cent confidence limits [CL]: 0.43, 1.31), 0.30 (95 per cent CL: 0.15, 0.60), and 0.51 (95 per cent CL: 0.33, 0.77) for follow-up within 15 weeks, beyond 15 weeks, and overall, respectively. Noncompliance correction using Robins and Finkelstein's (RF) inverse probability-of-censoring weights (where participants are censored at dropout or when first noncompliant) yielded estimated HR of 0.46 (95 per cent CL: 0.25, 0.85), 0.43 (95 per cent CL: 0.19, 0.96), and 0.45 (95 per cent CL: 0.27, 0.74) for follow-up within 15 weeks, beyond 15 weeks, and overall, respectively. Weights were estimated conditional on measured age, sex, race, ethnicity, prior Zidovudine use, randomized arm, baseline and time-varying CD4 cell count, and time-varying HIV-related symptoms. Noncompliance corrected results were 63 and 13 per cent farther from the null value of one than intent-to-treat results within 15 weeks and overall, respectively, and resolve the apparent non-proportionality in intent-to-treat results. Inverse probability-of-censoring weighted methods could help to resolve discrepancies between compliant and noncompliant randomized evidence, as well as between randomized and observational evidence, in a variety of biomedical fields. (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 19347843     DOI: 10.1002/sim.3585

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  45 in total

Review 1.  Application of marginal structural models in pharmacoepidemiologic studies: a systematic review.

Authors:  Shibing Yang; Charles B Eaton; Juan Lu; Kate L Lapane
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-01-24       Impact factor: 2.890

2.  Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias.

Authors:  Chanelle J Howe; Stephen R Cole; Joan S Chmiel; Alvaro Muñoz
Journal:  Am J Epidemiol       Date:  2011-02-02       Impact factor: 4.897

3.  Estimating causal effects from a randomized clinical trial when noncompliance is measured with error.

Authors:  Jeffrey A Boatman; David M Vock; Joseph S Koopmeiners; Eric C Donny
Journal:  Biostatistics       Date:  2018-01-01       Impact factor: 5.899

4.  Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007.

Authors:  Chanelle J Howe; Stephen R Cole; Sonia Napravnik; Joseph J Eron
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

5.  Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization.

Authors:  Sengwee Toh; Sonia Hernández-Díaz; Roger Logan; James M Robins; Miguel A Hernán
Journal:  Epidemiology       Date:  2010-07       Impact factor: 4.822

6.  Invited commentary: every good randomization deserves observation.

Authors:  Daniel Westreich; Jessie K Edwards
Journal:  Am J Epidemiol       Date:  2015-10-19       Impact factor: 4.897

7.  From exposures to population interventions: pregnancy and response to HIV therapy.

Authors:  Daniel Westreich
Journal:  Am J Epidemiol       Date:  2014-02-25       Impact factor: 4.897

8.  Effectiveness of treatment for adolescent substance use: is biological drug testing sufficient?

Authors:  Megan S Schuler; Beth Ann Griffin; Rajeev Ramchand; Daniel Almirall; Daniel F McCaffrey
Journal:  J Stud Alcohol Drugs       Date:  2014-03       Impact factor: 2.582

9.  Influence of Injection Drug Use-Related HIV Acquisition on CD4 Response to First Antiretroviral Therapy Regimen Among Virally Suppressed Individuals.

Authors:  Keri L Calkins; Catherine R Lesko; Geetanjali Chander; Richard D Moore; Bryan Lau
Journal:  J Acquir Immune Defic Syndr       Date:  2018-03-01       Impact factor: 3.731

10.  Estimating Human Immunodeficiency Virus (HIV) Prevention Effects in Low-incidence Settings.

Authors:  Jacqueline E Rudolph; Stephen R Cole; Joseph J Eron; Angela D Kashuba; Adaora A Adimora
Journal:  Epidemiology       Date:  2019-05       Impact factor: 4.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.